Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for non-ambulatory DMD patients with a confirmed mutation in the DMD gene on the 20th of ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock fall 3.3% in pre-market trading Thursday following the announcement of a refinancing of roughly $700 million of its 1.25% Convertible Senior Notes due ...

What To Know: Under privately negotiated exchange agreements, Sarepta will swap about $700 million in aggregate principal amount of its existing convertible notes for approximately $602 million in new ...

Sarepta Therapeutics ( ($SRPT) ) has provided an announcement. On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock declined 3.3% in pre-market trading Thursday after the company announced a refinancing of approximately $700 million of its 1.25% Convertible ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer talked about. A caller asked for Cramer’s outlook on the stock, and he commented: “Oh God. I was hoping it’s not Sarepta. I don ...